POMC and hyperlipidemia: Proopiomelanocortin (POMC), an appetite-inhibiting neuropeptide, is decreased by increased levels of appetite-stimulating neuropeptides such as neuropeptide Y (NPY) and agouti-related peptide (AgRP), which reduces energy expenditure, increases food intake, weight gain, and hyperlipidemia (49).